scholarly journals Understanding the cost of care of type 2 diabetes mellitus - a value measurement perspective

BMJ Open ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. e053001
Author(s):  
Gerardine Anne Doyle ◽  
Shane O'Donnell ◽  
Kate Cullen ◽  
Etáin Quigley ◽  
Sarah Gibney

ObjectivesWe explore the cost of care of type 2 diabetes mellitus (T2DM) using time-driven activity-based costing (TDABC) and connect that cost to resulting patient health outcomes.DesignWe construct six care pathways varying from low-risk to high-risk patients over a 12-month cycle of care. We collect time, resource and cost data on activities in each care pathway and compute a time-driven estimate of cost. Use of patient outcome data highlights the health outcomes achieved.SettingPrimary, secondary and tertiary care.ParticipantsMedical staff involved in the care of patients with T2DM.Primary and secondary measuresPrimary: resources consumed to provide T2DM care. Secondary: health outcomes for representative patient within each patient category.ResultsBy computing cost of T2DM care and associated complications of chronic kidney disease, active foot disease, moderate risk of active foot disease and myocardial infarction, we show that when patients develop acute complications, significant costs are incurred, as compared with the cost of maintaining a patient at low or moderate risk. Variance analysis further informs decision making by showing the need to have the right personnel doing the right tasks at the right time to control costs.ConclusionsA TDABC approach facilitates an understanding of the drivers of cost in chronic illness care. Our paper highlights the stages in the care pathway where different settings, decision making and a more optimal use of resources could assist with achievement of better patient outcomes.

2021 ◽  
Vol 13 (3) ◽  
pp. 1343
Author(s):  
José Carmelo Adsuar ◽  
Jose Parraca ◽  
Armando Raimundo ◽  
Miguel Angel Garcia-Gordillo ◽  
Patricia Polero ◽  
...  

Background: Reliability studies are used to verify the evaluation accuracy of a given device. Strength is an important factor for the development of daily activities and its correct management is fundamental. The objective of this study was to examine the reliability of a concentric strength test in people with type 2 diabetes mellitus (T2DM). Methods: Twenty-seven individuals with T2DM performed three repetitions of extension-flexion in concentric-concentric action at 60°/s, for both legs, using an isokinetic dynamometer. For the reliability analysis, we performed an intra-session test retest. Results: The total sample and men sub-group intra-class correlation coefficient (ICC) values were excellent for peak torque and work. In the women sub-group, ICC values were excellent for extensors in both peak torque and work; however, concerning flexor, the ICC values were good for peak torque while, for work, they were good for the right leg and moderate for the left leg. Standard error of measurement (SEM) percentage oscillated from 3.85% to 6.80%, with the smallest real difference (SRD) percentage being from 10.66% to 18.86% for peak torque. Furthermore, the SEM (%) was around 5.5% and SRD (%) was around 15% for work. Conclusions: The isokinetic dynamometry had “good” to “excellent” relative reliability for peak torque (0.862–0.983) and work (0.744–0.982) of extension-flexion in concentric-concentric action at 60°/s. In addition, our study showed that, in general, an SRD < 20% could indicate a true change in strength regarding this protocol in T2DM.


Author(s):  
Dnyanesh Limaye ◽  
Krishna Todi ◽  
Jay Shroff ◽  
Ashutosh Ramaswamy ◽  
Priyanka Kulkarni ◽  
...  

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness. 


ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 122-125
Author(s):  
Paola Ubaldi

Hypoglycemic therapy over the past 20 years has expanded considerably with the use of new classes of more effective and safer medicines. Alongside the aging of the general population, the survival of diabetic subjects has significantly increased, thus exposing them to a greater risk of developing co-morbidities. This represents a challenge for the diabetologist, who must acquire ever broader concepts for the management of a complex and multi-organ disease. We report the case of a 72-year-old woman with type 2 diabetes mellitus and pulmonary adenocarcinoma of the right upper lobe with brain and bone metastases who, subjected to innovative and integrated treatments agreed between specialists of different disciplines, is still alive and free of cancer symptoms 23 months after diagnosis (Diabetology)


2016 ◽  
Vol 35 (3) ◽  
pp. 375-396 ◽  
Author(s):  
Michael Willis ◽  
Pierre Johansen ◽  
Andreas Nilsson ◽  
Christian Asseburg

Sign in / Sign up

Export Citation Format

Share Document